Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05636943 · ClinicalTrials.gov registry record · NA

Couples' QOL in Metastatic Breast Cancer

A NA study of Metastatic Breast Cancer, sponsored by Fox Chase Cancer Center.

Active
Registry status
NA
Development phase
110
Enrollment target
1
Study location

NCT05636943 is a NA study of Metastatic Breast Cancer that is active but no longer recruiting, run by Fox Chase Cancer Center. The registered enrollment target is 110 participants, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (46% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05636943, a NA study of Metastatic Breast Cancer, is active but no longer recruiting, sponsored by Fox Chase Cancer Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
110 participants
Enrollment target
1
Study location

Study Summary

The primary objectives of this study are to adapt and evaluate a sexual quality of life intervention in women with metastatic breast cancer and their partners.

Conditions Studied

Interventions

  • BEHAVIORAL Adapted Intimacy Enhancement
  • BEHAVIORAL Intimacy Facts and Resources

Study Locations (1)

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2021-01-01
Est. Completion 2025-05-30
Phase NA

Sponsor

Fox Chase Cancer Center

183 total trials

What the Registry Record Tells You About NCT05636943

The ClinicalTrials.gov registry entry for NCT05636943 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (46% lower). The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Adapted Intimacy Enhancement is the first listed.

NCT05636943 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05636943 about?

NCT05636943 is a clinical study titled "Couples' QOL in Metastatic Breast Cancer". The primary objectives of this study are to adapt and evaluate a sexual quality of life intervention in women with metastatic breast cancer and their partners.

What is the current status of trial NCT05636943?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 110 participants. The study started on 2021-01-01. Estimated completion is 2025-05-30.

What conditions does trial NCT05636943 study?

This clinical trial studies the following conditions: Metastatic Breast Cancer.

What interventions are being tested in trial NCT05636943?

The interventions under investigation include: Adapted Intimacy Enhancement (BEHAVIORAL), Intimacy Facts and Resources (BEHAVIORAL).

Who is sponsoring clinical trial NCT05636943?

This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05636943 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metastatic Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.